

¹⁸⁸Re Zoledronic Acid in the Palliative Treatment of Painful Bone Metastases

Tatiana Kochetova^{1,*}, Valeriy Krylov¹, Maxim Smolyarchuk¹, Dmitriy Sokov², Alexander Lunev³, Sergey Shiryaev⁴, Olga Kruglova¹, Tatiana Makeenkova⁵, Karina Petrosyan¹, Alexandra Dolgova⁵, Marina Poluektova¹, Vsevolod Galkin¹ and Andrey Kaprin¹

¹National Medical Radiological Research Center" of the Ministry of Health of the Russian Federation, Korolev str. 4, Obninsk, Kaluga region, Russia

²Clinical Oncology Dispensary No1, Baumanskaya str. 17/1, Moscow, Russia

³Federal Medical Biophysical Center of FMBA, Russia, Zhivopisnaya str. 46, Moscow, Russia

⁴N.N. Blokhin Russian Cancer Research Center" of the Ministry of Health of the Russian Federation, Kashirskoe shosse, 24, Moscow, Russia

⁵Obninsk Institute for Nuclear Power Engineering, Studgorodok 1, Obninsk, Kaluga region, Russia

Abstract: ¹⁸⁸Re Zoledronic acid (¹⁸⁸Re-ZA) is new radiopharmaceutical which may have advantages over other bone seeking β -emitters due to high radiation energy of ¹⁸⁸Re, and metabolic effect of zoledronic acid.

In the phase I-II of the study therapeutic dosage of ¹⁸⁸Re-ZA was estimated. Pharmacokinetics, dosimetry and safety were assessed in the dose escalation study. Twenty-one (3, 3 and 15) breast and prostate cancer patients with multiple painful bone metastases received 35, 45 and 55 MBq of ¹⁸⁸Re-ZA respectively. In the next step 42 new patients were randomized in 2 groups (¹⁸⁸Re-ZA in dosage of 45 MBq/kg and ⁸⁹SrCl₂ in dosage of 150 MBq) to assess safety and efficacy of the radiopharmaceuticals, the follow up lasted for 9 weeks.

Absorbed dose to the bone marrow is respectively low 0.26±0.06 Gy. The dose escalation study shows that ¹⁸⁸Re-ZA the dosage of 55 MBq/kg is safe, no significant hematologic or any other toxicity is observed. ⁸⁹SrCl₂ in a dosage of 150 MBq, as compared to ¹⁸⁸Re-ZA in a dosage of 45 MBq/kg demonstrates similar efficacy, but the effect starts faster in ¹⁸⁸Re-ZA group. By the end of the follow up some patients demonstrated pain recurrence, this may indicate the need for repeated courses of treatment. Though many patients with widespread bone metastases and the higher base level of alkaline phosphatase were in the ¹⁸⁸Re-ZA group, in the majority of cases of both groups stabilization of the disease was achieved and continued for at least two months. Both radiopharmaceuticals demonstrated acceptable safety profile. Although trend in reduction of hemoglobin level was observed, especially in the group of patients with baseline anemia, both radiopharmaceuticals significantly impact on the platelet counts (PLT) only. As it was predicted by dosimetry data, ¹⁸⁸Re-ZA in a dose of 45 MBq/kg is safer, by the week 6 the PLT counts in the ¹⁸⁸Re-ZA group became almost the same as baseline and even higher in the week 9, while in the ⁸⁹SrCl₂ group in the week 9 PLT counts remained below the baseline; the difference was statistically proven. It seems that patients with breast cancer, in contrast to those with prostate cancer, have benefit (not statistically significant) in overall survival: 20.7 vs 15.6 months regardless dosage or type of radiopharmaceutical.

Keywords: Bone metastases, ¹⁸⁸Re-Zoledronic acid, Radiopharmacy, ¹⁵³Sm-EDTMP, ⁸⁹SrCl₂.

INTRODUCTION

For long time bone seeking radiopharmaceuticals are used to palliate painful bone metastases. Great part of scientific work in this area is focused on prostate and breast cancers. These types of cancers are characterized by frequent multiple bone metastases with no visceral lesions. [1]. Life expectancy of this kind of patients may be relatively long [1], so it is important to preserve their quality of life. Only three bone seeking radiopharmaceuticals are registered in Russia. ⁸⁹SrCl₂ and ¹⁵³Sm-EDTMP are the most commonly used to

decline pain syndrome and reduce analgesic intake. The newest bone seeking agent ²²³Ra dichloride also has benefit in overall survival of patients with castration resistant prostate cancer and predominantly skeleton involvement [2]. As for ⁸⁹SrCl₂ it is very simple to handle and administer, but it is recommended for use in cases of light to moderate pain syndromes and not widespread (less than 10 metastases) disease [3]. Unfortunately, these types of clinical situation are relatively rare. Due to its physical characteristics ¹⁵³Sm-EDTMP can be safely used for larger bone involvements, and its effect is faster, so it can help to manage severe pain [3]. As for ²²³Ra dichloride it is registered only for castration resistant prostate cancer patients and it is the most expensive one [4]. Despite the fact, that ²²³RaCl₂ is the gold standard of care of

*Address correspondence to this author at the National Medical Radiological Research Center" of the Ministry of Health of the Russian Federation, Korolev str. 4, Obninsk, Kaluga region, Russia; Tel: 007 919 034 58 38; Fax: 007 484 399 33 44; E-mail: tat_mail@inbox.ru

patients with multiple bone metastases, due to its high cost it is hardly available for majority of the prostate cancer patients in Russia and around the world. In addition, we still have no recommendations on the use of ²²³RaCl₂ in cases of other malignancies (not CRPC) with multiple painful bone metastases. Thus, the search for new radiopharmaceuticals is an important challenge. The new radiopharmaceutical based on ¹⁸⁸Re and Zoledronic acid may become an alternative to traditionally used bone seeking agents.

MATERIALS AND METHODS

Preparation of ¹⁸⁸Re Zoledronic Acid (¹⁸⁸Re-ZA)

¹⁸⁸Re perrhenate (radiochemical purity 99.7%, PH 4.1) was obtained from in-house 25 GBq ¹⁸⁸W/¹⁸⁸Re generator (Institute of Physics and Power Engineering, Obninsk). The generator was eluted with 5-9 ml of 0.9% saline. 1-2 ml of eluate was mixed with the preparation kit of 4 mg zoledronic acid lyophilizate (Pharm-Sintez, Moscow). The solution was heated at 95° C for 30 min, after cooling to room temperature the solution was passed through the sterilizing filter "Millipore" with the diameter of the pores 0,22 micrometers. Then it is added to 15 milliliters of saline solution and applied to patient by syringe pump for 15 minutes.

Quality control of ¹⁸⁸Re-ZA was performed using thin-layer chromatography developed with acetone or physiological saline. The levels of impurities detected in patient samples were always less than 5%.

Study Design

This study consisted of two parts. The aim of the first part was to assess the maximum tolerated dose of the radiopharmaceutical and estimate therapeutic dose. The first three patients had to receive the drug at a rate of 35 MBq/kg, after 8 weeks of safety assessment in the event of any dose-limiting toxicity (DLT) the group had to be expanded to 6 patients. In case of DLT in 2 subjects, the study had to be completed; otherwise it was necessary to recruit the next group of three with administration activity of 45 MBq/kg. Like in previous situation, in case of DLT the second group also had to be enlarged to 6 patients. If revealed 2 cases of DLT, the therapeutic dosage would be estimated as 35MBq/kg. In another case, it was necessary to recruit the third group of patients (55 MBq/kg), in case of DLT revealed during follow up period, the third group also had to be expanded to 6, if revealed 2 cases of DLT the therapeutic dosage would

be estimated as 45 MBq/kg. In case of only one or no DLT revealed the therapeutic dosage would be estimated as 55 MBq/kg. In any case the group of therapeutic activity had to be enlarged up to 15 patients in order to have more statistically significant data. The DLT was equal for the following events: neutropenia of grade IV or fever caused by neutropenia, grade IV platelet counts decrease or grade III thrombocytopenia lasted more than 7 days, any other grade III-V adverse event associated with the use of an investigational drug.

In the second part of the study safety and efficacy of ¹⁸⁸Re-ZA had to be assessed in comparison to ⁸⁹SrCl₂ on a randomized multicenter basis. The history of use of ¹⁸⁸Re-HEDP in Russia is limited only to clinical trials, and ¹⁸⁶Re-HEDP has never been used. ⁸⁹SrCl₂ is used in the majority of the nuclear therapy centers in Russia, but only two centers have experience in ¹⁵³Sm-EDTMP application. Therefore, ⁸⁹SrCl₂ was chosen as a comparative drug. Changes in quality of life, intensiveness of pain syndrome and metabolic response (according to a bone scan) were selected as effectiveness criteria. After active part of the investigation all patients entered into long term follow up period with assessment of overall survival.

Inclusion Criteria

Patients with histologically proven prostate or breast cancer and CT proven multiple (3 or more) painful (required analgesic intake) bone metastases with positive ^{99m}Tc Zoledronic acid uptake, with no history of visceral metastases and no additional malignancies were included in the study. Subjects with changes in hormone therapy, received external beam therapy or chemotherapy 1 month prior to screening were not included. Sufficient bone marrow function was required: platelet count not less than 100 thousand/ml, leukocyte count not less than 3.0 thousand/ml and hemoglobin level not less than 80 g/l.

Patients

The study was approved by the local ethics committee. All patients included in the study were informed about the study, possible risks of participation and signed the informed consent form.

According to the study design the first 3 patients with multiple painful bone metastases of prostate or breast cancer received ¹⁸⁸Re-ZA in dosage of 35 MBq/kg, as no cases of DLT appeared in follow up

period, the next 3 received 45 MBq/kg, and the third 3 – 55 MBq/kg, after 9 weeks of follow up the third group was enlarged up to 15 patients. All patients had previously done bone scan with ^{99m}Tc Zoledronic acid, theranostic pare to $^{188}\text{Re-ZA}$, 3 or more bone lesions were confirmed in each case. In the first day after administration dosimetry data were collected: 1, 4, 20, 26-28 hours after administration there was anterior and posterior whole body scanning performed (gamma-camera Mediso with high-energy collimator). Regions of interests were processed anterior and posterior: metastatic lesions, significant organs and tissues. Half-life time (T_{eff}), fractions of organs and absorbed doses were calculated using MCNP 4 code and program OLINDA/EXM 1.0. Safety assessment performed during the first 3 days after administration and then weekly up to week 9. For this issue, blood counts, liver and kidney function biomarkers (ALT, AST, creatinine, urea, etc) were obtained. Physical examination, electrocardiogram and urine tests were performed on a regular basis.

For the efficacy assessment 42 patients were included in the study, after screening they were randomized into $^{188}\text{Re-ZA}$ group and $^{89}\text{SrCl}_2$ group, 21

subjects for each group. Basic demographic data and screening characteristics of subjects are on the Figure 1. All patients kept a diary of pain and consumption of analgesics a week prior and during follow up period after administration of 45/kg MBq $^{188}\text{Re-ZA}$ or 150 MBq $^{89}\text{SrCl}_2$. In the diary, they daily described their pain in various parts of the body for a 10-point visual analog scale. Quality of life was evaluated using the SF-36 questioner, which was filled prior therapy and on the 28th and 56th day after. Safety control was performed by the method similar to that used in the first part of the investigation. All patients underwent bone scan with ^{99m}Tc Zoledronic acid in order to assess metabolic response.

RESULTS

Therapeutic Dosage of $^{188}\text{Re-ZA}$

In this study $^{188}\text{Re-ZA}$ did not demonstrate significant toxicity in any subgroup. In the group received 55MBq/kg of the radiopharmaceutical reversible short term neutropenia grade III was observed only once in breast cancer patient, who previously received multiple cycles of chemotherapy.

Subjects characteristics (screening)	The studied group				
	188Re-ZA 35 MBq/kg	188Re-ZA 45 MBq/kg (part 1)	188Re-ZA 55 MBq/kg	188Re-ZA 45 MBq/kg (part 2)	150 MBq ^{89}Sr chloride
Number of subjects (prostate and breast cancer)	3 2 and 1	3 1 and 2	15 4 and 11	21 10 and 11	21 11 and 10
Age (years) of prostate cancer ones	81 and 64	77	52, 55, 59 and 68	From 53 to 80, median 67	From 59 to 74, median 65
Age (years) of breast cancer ones	57	66 and 67	From 30 to 67, median 51	From 35 to 69 median 59	From 45 to 77 median 55
Number of patients divided in 4 groups depending on number of lesions found on bone scan:					
From 3 to 6	1 (33%)	0	1 (7%)	2 (10%)	4 (19%)
From 6 to 20	0	0	5 (33%)	5 (24%)	5 (24%)
More then 20, but not total	2 (67%)	2 (67%)	1 (7%)	5 (24%)	5 (24%)
Multiple lesions from scull to long bones	0	1 (33%)	8 (53%)	9 (43%)	7 (33%)
ALP level U/L (range and mean +/- SE)	48, 71 and 190	171, 234 and 905	43 to 961, mean 238 +/-62	57 to 1880, mean 345 +/- 98	61 to 508, mean 155 +/-27
HGB level g/l (range and mean +/- SE)	116, 120 and 139	113, 125 and 136	91 to 144, mean 126 +/-4	85 to 148, mean 124 +/-4	102 to 156, mean 132 +/-4
PLT $10^9/\text{L}$ (range and mean +/- SE)	171, 197 and 240	250, 283 and 435	137 to 363, mean 241 +/-15	143 to 347, mean 218 +/-14	129 to 564, mean 245 +/-20
WBC $10^9/\text{L}$ (range and mean +/- SE)	3.8, 6.7 and 6.9	6.2, 7.5 and 9.1	3.3 to 9.5, mean 6.5 +/- 0.5	3.9 to 13.6, mean 6.9 +/-0.5	4.2 to 13.4, mean 7.4 +/-0.6

Figure 1: Basic demographic data and screening characteristics of subjects included into the study.

Thus, DLT was not observed and ¹⁸⁸Re-ZA can be safely administered in dosage of 55 MBq/kg. However, according to the experts' opinion, estimated therapeutic dosage was 45 MBq/kg. This opinion was based on the idea that this kind of treatment might be more effective if it is repeated several times with relatively short intervals. The dosage was reduced to avoid any kind of cumulative toxicity in case of multiple cycles.

Dosimetry

During the first part of the study dosimetry measurements were carried out. Urine samples demonstrated rapid excretion of the drug, more than 90% excretion accounted for the first 4 hours after

administration. Half-life (T_{eff}) in bone metastasis (10.7 ± 3.7 h) depended on their size and uptake of the radiopharmaceutical; it was significantly higher than in a whole body (6.3 ± 0.7 h), normal organs and bones. Variation of T_{eff} determines variability of specific absorbed dose, which was adjusted to therapeutic activity of 45 MBq/kg. Absorbed dose in metastases varied from 4.68 to 43.89 Gy (tumor volume ranges from 14 to 70 cm³), which is sufficient to achieve therapeutic effect. Absorbed dose in kidneys (2.73 ± 0.67 Gy) and urinary bladder (4.24 ± 1.52 Gy) were less than maximally acceptable of 10 Gy. In this study, it was found that absorbed dose to the bone marrow was 0.26 ± 0.06 Gy, it is significantly lower than those for other commercially available bone seeking

	35 MBq/kg	45 MBq/kg	55 MBq/kg	all
PLT decrease	2 (67%)		9 (60%)	11 (52%)
Anemia		2 (67%)	5 (33%)	7 (33%)
Anemia grade II			2 (13%)	2 (10%)
WBC decrease	3 (33%)	1 (33%)	5 (33%)	7 (33%)
WBC decrease grade II			2 (13%)	2 (10%)
Neutropenia			4 (27%)	4 (19%)
neutropenia grade II			1 (7%)	1 (5%)
neutropenia grade III			1 (7%)	1 (5%)
PLT increase			4 (28%)	4 (19%)
WBC increase			3 (20%)	3 (14%)
HGB increase			1 (7%)	1 (5%)
hypercalcemia			3 (20%)	3 (14%)
hypocalcemia		1 (33%)	1 (7%)	2 (10%)
uremia			1 (7%)	1 (5%)
flare effect	3 (100%)	2 (67%)	7 (47%)	12 (57%)
flu like syndrome			3 (20%)	3 (14%)
flu like syndrome grade II			1 (7%)	1 (5%)
bone pain recurrence	3 (100%)		3 (20%)	6 (29%)
Urethritis	1 (33%)		6 (49%)	7 (33%)
nausea		1 (33%)	1 (7%)	2 (10%)
vomiting			1 (7%)	1 (5%)
anxiety			2 (13%)	2 (10%)
disorientation	1 (33%)			1 (5%)
local reaction			2 (13%)	2 (10%)
headache			1 (7%)	1 (5%)
arthrosis			1 (7%)	1 (5%)

Figure 2: List of adverse events possible related to study medication. The data collected during the first part of the study (therapeutic dose determination and safety assessment).

radiopharmaceuticals like $^{153}\text{Sm-EDTMP}$ (1.1 Gy) or even $^{188}\text{Re-HEDP}$ (2.0 ± 0.6) [5].

Safety

According to the study design administered activity of $^{188}\text{Re-ZA}$ was ranged from 2.7 to 5.8 GBq. In this study, adverse events were classified according to the NCI CTC AE v 4.0. In generally the therapy was well tolerated (Figure 2), only one serious adverse event (SAE) was reported in the group of 55 MBq/kg. Hormone refractory prostate cancer patient with rapid disease progression and severe pain syndrome (opioid use required) needed to prolong his stay at hospital due to the grade II flu-like syndrome (3 days of fever) and flare phenomenon which decreased his Karnofsky's scale from 60% to 40%. Two weeks later this patient was pain free with no more opioid intake and 70% Karnofsky's scale, there were not additional treatments of any kind and unfortunately 3.6 months later he died due to disease progression. Almost half of the patients noted the flare effect, which was manifested by a slight increase in pain or an increase in analgesics consumption. Flu like syndrome was documented in 14% of cases. By the end of the follow up period some patients (predominantly with prostate cancer) demonstrated bone pain recurrence that might be an indication for additional treatment cycle. Most common adverse effects which may have any connection to the study drug are listed on the Figure 2.

The most important adverse event of bone seeking radiopharmaceuticals is hematological toxicity. Platelet counts (PLT) is the unique setting which was found to be statistically significantly associated with the therapy. We have also identified significant differences between the two study drugs. Nevertheless, $^{188}\text{Re-ZA}$ was well tolerated in all subgroups of activity: 9 (60%) and 12 (63%) cases of grade I PLT decrease were found in 55 MBq/kg and 45 MBq/kg subgroups respectively, nadir was registered at the week 4 after the treatment date and the average PLT reduction was 12% (55 MBq/kg) and 17% (45 MBq/kg) respectively; and one case of reversible PLT counts grade II decrease was registered in one prostate cancer patient from the 45 MBq/kg group, his base PLT count was $103 \times 10^9/\text{l}$, by the week 9 it rose up to $125 \times 10^9/\text{l}$. No difference between the dosages of 45 MBq/kg and 55 MBq/kg (see Figure 3) was found. As for $^{89}\text{SrCl}_2$, in generally it was also well tolerated. No flu like syndrome was revealed, flare phenomenon also was not documented, but in one case (castration resistant prostate cancer) unexpectedly pancytopenia was developed, which

finely led to death. Except this one extraordinary case there was only grade I toxicity in 9 cases (45%). The differences between $^{188}\text{Re-ZA}$ and $^{89}\text{SrCl}_2$ are shown on the Figure 4. We presented data on those patients, who successfully completed the study without any protocol deviations, we excluded 2 women with disease progression (found brain metastases and pleura canceramatosi) from $^{188}\text{Re-ZA}$ drug arm, as for $^{89}\text{SrCl}_2$ arm, 2 men with progression of the disease, they could not follow the schedule of visits due to worsening of their general condition, 4 other patients missed at least one visit for different reasons and didn't take part in the evaluations. Remarkable, in the patient with severe PLT counts decrease necessary platelet transfusion at the week 8 of follow up, however this extraordinary case had not any influence on the final analysis. As it shown on the Figure 4, PLT counts are better in the $^{89}\text{SrCl}_2$ group (but not statistically significantly). At the week 1 unexpected increase in PLT counts in the $^{188}\text{Re-ZA}$ group was found. $^{188}\text{Re-ZA}$ acid PLT dynamics curve has a nadir at the week 4, then it goes up, is close to the screening value at the week 6, at the week 9 it is even better than before the treatment. $^{89}\text{SrCl}_2$ curve also seems to have a slight increase at the week 1, but its nadir is registered at the 5th week, after that the curve goes up slowly and doesn't reach initial values by the end of the follow up. Multivariate analysis of variance for repeated measures was used to found statistical differences between the two groups, and it was found with p value about 0.024. This distinction is very important for patients, who may need frequent retreatments to manage multiple painful bone metastases or some kind of chemotherapy in case of any needs.




Figure 3: Platelet count (PLT) dynamics after administration of 55 MBq/kg or 45 MBq/kg of $^{188}\text{Re-ZA}$. The number of valid (without missing points) cases were 12 and 19 respectively.




Figure 4: Platelet count (PLT) dynamics after administration of 45 MBq/kg of ¹⁸⁸Re-ZA or 150 MBq of ⁸⁹SrCl₂. The number of valid (without missing points) cases were 18 and 15 respectively.

As for other blood parameters, we noticed slight, not statistically significant, decrease of hemoglobin (HGB) level and white blood cell counts (WBC) after administration of ¹⁸⁸Re-ZA or ⁸⁹SrCl₂ with no difference depended on the drug or its dosage. There were two cases of anemia grade II. The first occurred in the previously described patient from the ¹⁸⁸Re-ZA 55 MBq/kg group, the HGB level declined from 91 to 81 g/l with subsequent full recovery. The other case also appeared in hormone refractory prostate cancer patient: HGB level dropped down from 107 g/l to 97 g/l by the end of the follow up period. We did not found any statistically significant changes in influence on HGB level between ¹⁸⁸Re-ZA and ⁸⁹SrCl₂. There were 3 cases (16%) of anemia grade III in ¹⁸⁸Re-ZA group. All subjects were previously anemic with HGB level dropped from 91, 86, and 85 g/l to 79, 70 and 74 g/l respectively. Remarkably, two anemic patients had progressive hormone refractory prostate cancer after multiple cycles of chemotherapy and one breast cancer patient demonstrated specific hemorrhagic pleural effusion 5 weeks after administration. In addition, there was 1 case (5%) of anemia grade II in hormone refractory prostate cancer patient which had anemia grade I at the screening time. In the ⁸⁹SrCl₂ group no patients with HGB level below the rate 100 g/l at the screening time were included, but 1 case (5%) of grade III anemia also was reported in man with previous grade I anemia, and 4 cases (20%) of grade II anemia were found, only one of them had normal HGB level at the time of administration. In both groups, there were patients with normal HGB level at the time of administration who did not demonstrate any decline of the HGB level at all. The data shows that some

circumstances, like disease progression, bone marrow involvement and others, in addition to medications can affect the severity of anemia. In all groups of subjects WBC counts fluctuated in normal range, those patients who initially had WBC count higher than normal level tended to have a decline after treatment. In patients, who were heavily pretreated with chemotherapies, some cases of hematological toxicity were documented. In ¹⁸⁸Re-ZA (55 MBq/kg) group 4 cases (27%) of grade I and 2 cases (13%) of grade II reversible WBC decrease was found, in ¹⁸⁸Re-ZA (45 MBq/kg) 5 cases (26%) of grade I WBC decrease were documented, in the ⁸⁹SrCl₂ group 6 cases (30%) of grade I and 1 case (5%) of grade II WBC decrease were found.

Efficacy

The main idea of the efficacy analysis was to evaluate the influence of administration of ¹⁸⁸Re-ZA or ⁸⁹SrCl₂ on the average severity of pain. For this issue the area under the pain-time curve (AUC) was calculated for the 7 days of screening period and weekly after the treatment. For comparative analysis, the generalized linear model was used. In our small study (19 and 18 valid subjects who completed all diaries in ¹⁸⁸Re-ZA and ⁸⁹SrCl₂ group respectively) there was not found any statistically significant deference. In both groups, there were some cases with severe pain syndrome which was refractory to treatment demonstrated only aggravation during the follow up period. These few cases have a great impact on the means, thus the medians reflect the real dynamic much more accurately. As one can see on the Figure 5, patients treated with ⁸⁹SrCl₂ had better initial conditions, in the 1st 3 weeks we can not see any positive changes, this data is well correlated with already known property of ⁸⁹SrCl₂. From the week 3 the AUC pain-time curve goes down but unfortunately does not reach its nadir. So, we can't make any conclusions neither about decline degree nor about duration of effect. Contrary, ¹⁸⁸Re-ZA demonstrated fast analgesic effect. Feeling better many patients tried to reduce their daily analgesic intake, what was the reason of pain recurrence at the week 2. After this peak the curve continues to decrease till its nadir at the week 5, average of decrease at this point compared to the screening time is 25.47% for the medians and 10.47% for the means. At the end of the follow up period there was a tendency to evidence of pain recurrence followed with a return to analgesics use. At the week 9 only 4 (21%) patients still demonstrated 50% reduce in the index of analgesic intake, while in ⁸⁹SrCl₂ group at

its best time of action 6 (33%) subjects had 50% or more reduction of this index. To conclude, these even not statistically significant tendencies may indicate a need for different therapeutic approaches in use the investigational drugs.




Figure 5: Area under the curve “Pain-Time” (AUC) at the screening week and after administration of investigational and control radiopharmaceutical.

As for quality of life at the week 4 the dynamics of the integral index of quality of life (IQL) was better in $^{188}\text{Re-ZA}$ group than in $^{89}\text{SrCl}_2$ one (+10% and +3% respectively). Like in previous analysis results for $^{89}\text{SrCl}_2$ group were better at the week 9, IQL reached +7%, while in $^{188}\text{Re-ZA}$ it was measured +6% compared to the screening condition. These differences however did not reach statistical significance. In subgroup analysis, we found that in the breast cancer group $^{188}\text{Re-ZA}$ was managed to improve physical component of quality of life (-2% at the week 4 and +21% at the week 9), while $^{89}\text{SrCl}_2$ failed to improve it (-3% at the week 4 and -1% at the week 9). The differences between $^{188}\text{Re-ZA}$ and $^{89}\text{SrCl}_2$ arms were statistically significant according to the Wilcoxon test ($p < 0.05$). In male patient group any statistically significant differences were not found.

Metabolic Response

All patients had bone scan with $^{99\text{m}}\text{Tc-ZA}$ prior to administration of $^{188}\text{Re-ZA}$ or $^{89}\text{SrCl}_2$, those who successfully completed the study had control bone scan on the last visit, at the week 9. Alkaline Phosphatase (ALP) was measured weekly before and after the administration. In both groups, more than half patients had wide spread bone metastases (more than 20 lesions), see Figure 1. Unfortunately, we found statistically significant difference between the main and control group in the baseline ALP level, which, as

known, correlates with prognosis. In the $^{188}\text{Re-ZA}$ group it was significantly higher. Generalized linear model was used to assess influence of the therapy on the ALP level, which can reflect metabolic response, see Figure 6. In this study, there was not any differences between initial and follow up ALP level; it was stable in both groups. In individual analysis, by the end of the follow up period we found 2 cases (12%) of ALP progression (more than 30% ALP level increase) and 3 cases (18%) of response (more than 30% ALP level decrease) in the $^{188}\text{Re-ZA}$ group. In $^{89}\text{SrCl}_2$ group there were 2 cases of progression (11%) and only 1 responder (5%). As for imaging, we saw generally stable disease or mix response, there were 4 cases (20%) of 2 or more new active bone lesions on bone scan in the $^{188}\text{Re-ZA}$ group and 5 (25%) in the $^{89}\text{SrCl}_2$ group. We also found one case (5%) of clear metabolic response (two lesions disappeared) in the control group.




Figure 6: ALP dynamics after administration of $^{188}\text{Re-ZA}$ (45 MBq/kg) or $^{89}\text{SrCl}_2$ (150 MBq).

Survival

All patients included in the study and received treatment entered into survival analysis. Some of them unfortunately were lost for long term follow up, but the data is still collected, so this time we can present only preliminary results. We assessed overall survival (OS) in 3 groups of patients: $^{188}\text{Re-ZA}$ 55 MBq/kg, $^{188}\text{Re-ZA}$ 45 MBq/kg and $^{89}\text{SrCl}_2$ 150 MBq. The results are presented on the Figure 7, The curves are very close to each other, median OS was 17,9 months for $^{188}\text{Re-ZA}$ 55 MBq/kg (15 subjects), 15,8 months for $^{188}\text{Re-ZA}$ group 45 MBq (24 subjects) and for $^{89}\text{SrCl}_2$ 150 MBq (21 subjects) the OS still not estimated. No statistically significant difference between the groups was found, so we tried to compare OS in men (28 subjects) and

women (35 subjects), see Figure 8. It seems that life expectancy in breast cancer patients (median OS – 20,7 months) is better than in prostate cancer males (median OS – 15,6 months), but the difference is not statistically significant.




Figure 7: Overall survival by groups: ¹⁸⁸Re-ZA 55 MBq/kg, ¹⁸⁸Re-ZA 45 MBq/kg and ⁸⁹SrCl₂ 150 MBq.




Figure 8: Overall survival in breast and prostate cancer patients after one cycle of bone seeking radiopharmaceutical.

DISCUSSION AND CONCLUSION

¹⁸⁸Re-ZA is promising radiopharmaceutical for treatment painful bone metastases. Firstly, we noticed a great difference in pharmacokinetic compared to other bone seeking radiopharmaceuticals and even ¹⁸⁸Re-HEDP [5], Zoledronic acid has the highest affinity to bone lesions (compared to other phosphonates) with minimal accumulation in healthy bones [6]. As result, therapeutic absorbed doses in bone lesions can be achieved with relatively low bone marrow irradiation. Features of the distribution allow using ¹⁸⁸Re-ZA in

higher dosages than ¹⁸⁸Re-HEDP: 55 MBq/kg (up to 5.8 GBq) of ¹⁸⁸Re-ZA is safe and acceptable while for ¹⁸⁸Re-HEDP therapeutic activity was estimated as 3.3 GBq [7]. Bone seeking radiopharmaceuticals are well tolerated; well known dose limiting toxicity is a delayed decrease in the number of blood counts, mainly PLT. The decrease in the PLT counts by the week 4 after the administration, apparently, is a common feature of bone seeking radiopharmaceuticals, a similar trend recorded for ¹⁵³Sm-EDTMP [8]. In this study, we didn't find any significant impact on WBC or HGB level of the both drugs, but there was a tendency to HGB level decline, especially in anemic subjects. In this cases anemia may be the consequence of bone marrow involvement and disease progression, previous cytotoxic regimens or malabsorption and malnutrition. The influence of therapy on the severity of anemia remains not clear. But in fact, inclusion criteria were very wide allowing anemic patients with HGB level below 100 g/l to be involved in this study. There were 2 anemic patients with HGB level 86 g/l and 1 patient – 91 g/l. They all demonstrated worsening the anemia down to grade III which reversed by the end of the follow up period only in one case. In contrast, no decline in HGB level in non-anemic persons was found.

According to the study the therapy had clear influence on PLT counts. In previous investigations no difference between various bone seeking radiopharmaceuticals (¹⁵³Sm-EDTMP, ¹⁸⁸Re-HEDP and ⁸⁹SrCl₂) was found [9]. ¹⁸⁸Re-ZA is the first one that demonstrated preferable safety profile compared to ⁸⁹SrCl₂. That is very important for planning retreatments or combinations with other cytotoxic regimens. The case of unexpected pancytopenia in previously clinically stable prostate cancer patient also noteworthy. There is not any clear data about limitations in ⁸⁹SrCl₂ usage, IAEA recommends not to use it in cases with more than 10 bone lesions (according to bone scan) [3], however, no national or other recommendations related to this subject; in the study 57% patients from the control group, who received ⁸⁹SrCl₂, had more than 20 bone lesions. Thus, that is a question for further investigations. Despite the fact that patients treated with ¹⁸⁸Re-ZA had worse base condition (higher ALP level), than patients of the control group, both radiopharmaceutical demonstrated similar efficacy. But ¹⁸⁸Re-ZA acts faster and there is a tendency to pain recurrence in some cases at the week 9, while analgesic effect of ⁸⁹SrCl₂ starts two weeks later and by the week 9 it appears to be maximum. Thus ¹⁸⁸Re-ZA is more suitable for those who suffer

from severe uncontrolled or progressive pain syndrome. Breast cancer patients from the $^{188}\text{Re-ZA}$ group had statistically significant benefit in physical component of IQL. Both radiopharmaceuticals were able to achieve stabilization in ALP level.

The study is too small to draw any evidence-based conclusions about survival, however, it should be noted that we have not found any significant difference between patients received a single cycle of $^{89}\text{SrCl}_2$ or $^{188}\text{Re-ZA}$ in different dosages. It seems that breast cancer patients have better prognosis than prostate cancer ones, in order to prove this, we need more data. In any case, our survival rates look good compared with findings from other studies [10], including large randomized trials like ALSIMPCA trial [11]. That is encouraging and inspires further research in the field of application of bone seeking β -emitters.

ACKNOWLEDGEMENTS

We thank our sponsor and developer of the drug AO "Pharm-Sintez"; the patients volunteered in the study; study centers staff who cared for them; the sponsor staff involved into data collection: Diana Grigorieva, Elena Gavrickaya, Roman Manuylov; and Lev Volosnev for conduct of the trial and helped us at every step of it.

REFERENCES

- [1] Coleman RE. Skeletal complications of malignancy. *Cancer* 1997; 80(8 Suppl): 1588-94
[https://doi.org/10.1002/\(SICI\)1097-0142\(19971015\)80:8+<1588::AID-CNCR9>3.0.CO;2-G](https://doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G)
- [2] Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM. Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: an update on literature with case presentation. *Int J Mol Imaging* 2016 Jun 16; Article ID 2568031, 12 pages. Available from:
<https://doi.org/10.1155/2016/2568031>
- [3] Agarwal JP, Baum RP, Hoefnagel CA, Hoskin P, Mount Kim EE, Mariani G *et al.* Criteria for palliation of bone metastases – clinical applications IAEA, Vienna 2007 IAEA-TECDOC-1549:40-9
- [4] Norum J, Traasdahl ER, Totth A, Nieder C, Olsen JA. Health economics and Radium-223 (Xofigo®) in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a case history and a systematic review of the literature. *Glob J Health Sci* 2015; 8(4): 1-9
<https://doi.org/10.5539/gjhs.v8n4p1>
- [5] Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF Jr, Franke WG. Dosimetry of ^{188}Re -hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. *J Nucl Med* 2003; 44(6): 953-60
- [6] Nacollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W *et al.* Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. *Bone*. 2006; 38(5): 617-27
<https://doi.org/10.1016/j.bone.2005.05.003>
- [7] Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grünwald F, Knapp FF Jr, Biersack HJ. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. *Eur J Nucl Med* 2000; 27(2): 123-30
<https://doi.org/10.1007/s002590050017>
- [8] Weiss K, Palumbo B, Palumbo I, Palumbo R, Granegger S, Hiltunen J, Sinzinger H. Platelet function after single [^{153}Sm] EDTMP therapy in prostate cancer. *Q J Nucl Med Mol Imaging* 2006; 50(4): 330-3
- [9] Liepe K, Kotzerke J. A comparative study of ^{188}Re -HEDP, ^{186}Re -HEDP, ^{153}Sm -EDTMP and ^{89}Sr in the treatment of painful skeletal metastases. *Nucl Med Commun* 2007; 28(8): 623-30
<https://doi.org/10.1097/MNM.0b013e32825a6adc>
- [10] Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. *Cancer Treat Rev* 2008; 34(2): 183-92
<https://doi.org/10.1016/j.ctrv.2007.10.002>
- [11] Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossà SD *et al.* Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369(3): 213-23
<https://doi.org/10.1056/NEJMoa1213755>

Received on 01-03-2017

Accepted on 07-04-2017

Published on 31-07-2017

<http://dx.doi.org/10.15379/2408-9788.2017.08>

© 2017 Kochetova *et al.*; Licensee Cosmos Scholars Publishing House.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.